
NIVOPOSTOP: Adjuvant Nivolumab After Surgery in High-Risk Locally Advanced Head and Neck Cancer
Dr. Sun walks through NIVOPOSTOP: adjuvant nivolumab added to cisplatin–radiation in surgically resected locally advanced head and neck cancer with high-risk features.
Jahan:Welcome to this Between the Lines with CancerNetwork. My goal in the next few minutes is to take a piece of new evidence and make it clear and useful — the kind of explanation that a busy colleague or an informed patient could easily follow. Let’s get started.
Sun:My name is Fangdi Sun. I am a head and neck medical oncologist at Stanford University.
Jahan:I’m Nusrat Jahan, a medical oncologist at UT Southwestern. My clinical focus is breast cancer and clinical trials.
Sun:Today the area I’ll take us to is the locally advanced setting for head and neck cancer that has been surgically resected. Let me set the stage. These are largely oral cavity cancers, with some larynx and hypopharynx. For at least a decade, our standard of care has been upfront surgery followed by radiation for many of these locally advanced cases, with or without chemotherapy depending on high-risk features. Before the trial I’ll discuss, the one trial that moved things a bit added immunotherapy both before and after surgery, which did improve some clinical outcomes. But implementation is challenging — for a head and neck cancer patient with significant tumor-related pain, or in whom you’re worried about progression before surgery, giving immunotherapy alone upfront is a difficult proposition.
Sun:The study we’ll be talking about is NIVOPOSTOP — and I think that title is actually quite illustrative. This was a study of adding nivolumab, a PD-1 inhibitor, after surgery. It enrolled patients with stage III or IVA locally advanced disease who had gone to surgery and then had high-risk features on their final pathology. There are several such features, but the most important are extranodal extension and positive margins. Patients were randomized to receive either the standard of care — cisplatin plus radiation — or that therapy along with adjuvant nivolumab, with most patients receiving adjuvant immunotherapy for about 7 to 8 months. The major takeaway is that patients who received nivolumab had improved disease-free survival. This is where it gets a little controversial.
Related to this article







